BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/12/2020 6:46:53 AM | Browse: 63 | Download: 46
Publication Name World Journal of Diabetes
Manuscript ID 54009
Country/Territory Greece
Received
2020-01-04 11:30
Peer-Review Started
2020-01-04 11:32
To Make the First Decision
Return for Revision
2020-02-25 21:20
Revised
2020-02-29 10:29
Second Decision
2020-04-04 06:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-04-05 16:12
Articles in Press
2020-04-05 16:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-04-23 23:50
Publish the Manuscript Online
2020-05-11 09:58
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology and Metabolism
Manuscript Type Editorial
Article Title Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
Manuscript Source Invited Manuscript
All Author List Stelina Alkagiet and Konstantinos Tziomalos
Funding Agency and Grant Number
Corresponding author Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Keywords Heart failure; Type 2 diabetes mellitus; Sodium-glucose co-transporter-2 inhibitors; Canagliflozin; Dapagliflozin; Empagliflozin
Core Tip Sodium-glucose co-transporter-2 inhibitors substantially reduce the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). Accordingly, these agents should be considered in all patients with T2DM and HF with reduced left ventricular ejection fraction regardless of HbA1c levels. However, more studies are needed to clarify the role of sodium-glucose co-transporter-2 inhibitors in patients with T2DM and HF with preserved left ventricular ejection fraction, which is the commonest type of HF in this population.
Publish Date 2020-05-11 09:58
Citation Alkagiet S, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. World J Diabetes 2020; 11(5): 150-154
Url https://www.wjgnet.com/1948-9358/full/v11/i5/150.htm
DOI https://dx.doi.org/10.4239/wjd.v11.i5.150
Full Article (PDF) WJD-11-150.pdf
Full Article (Word) WJD-11-150.docx
Manuscript File 54009-Review.doc
Answering Reviewers 54009-Answering reviewers.pdf
Audio Core Tip 54009-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 54009-Conflict-of-interest statement.pdf
Copyright License Agreement 54009-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 54009-Language certificate.pdf
Peer-review Report 54009-Peer-review(s).pdf
Scientific Misconduct Check 54009-Scientific misconduct check.pdf
Scientific Editor Work List 54009-Scientific editor work list.pdf